Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional

Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Cannaxan GmbH, Apurano Pharmaceuticals GmbH

Enrolment target

558

Start

05 Apr 2023

Chronic pain due to central Neuropathy of any Genesis

What is this study about?

1) Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)

Who may be eligible?

Age 18 Years to any · Sex: All

Locations (2)

—
Austria
—
Germany

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.